Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Cancer Letters
Cite this paper
Plain citation
Zhaokai Zhou, Yumiao Mai, Ge Zhang, Yingjie Wang, Pan Sun, Zhaohe Jing, Zhengrui Li, Yudi Xu, Bo Han, Jian Liu. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Letters. 2024. https://doi.org/10.1016/j.canlet.2024.217079
Research context and source limits
Limited evidence note. Only the source material identified below has been reviewed; this is not a complete Paper GEO V2 assessment.
Abstract-supported review context; the complete review and its cited experimental evidence have not been audited.
Review question
This review considers immunogenic cell death as a possible partner for CAR-T strategies in solid tumors. Its abstract connects stress-induced release of damage-associated molecular patterns with the immune environment and describes antigen heterogeneity and physical or immune barriers as challenges for CAR-T cells.
Source: PubMed PMID 38936505, Abstract: opening rationale and solid-tumor barriers.
Evidence level
The article is a review of mechanisms and proposed combination approaches, not a new clinical trial. Its discussion of potential synergy should be distinguished from demonstrated patient benefit for a specific regimen.
Evidence limits
- Specific combinations, experimental models and effect sizes require the complete review and the relevant primary studies. The available abstract cannot establish prospective clinical efficacy or safety.
Provenance
- Indexed article abstract — PubMed abstract, refreshed through the official Europe PMC API. PubMed PMID 38936505, Abstract: opening rationale and solid-tumor barriers.
Source review: 2026-10-27.
Verify publication identity
These records identify the same original work; database inclusion is not evidence of scientific validity or clinical benefit.